Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Accounts Payables (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Accounts Payables for 4 consecutive years, with $940761.0 as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 20.16% to $940761.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $940761.0, a 20.16% increase, with the full-year FY2024 number at $987311.0, up 63.25% from a year prior.
  • Accounts Payables was $940761.0 for Q3 2025 at bioAffinity Technologies, down from $1.2 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $1.4 million in Q1 2025 to a low of $146537.0 in Q1 2023.
  • A 4-year average of $672505.0 and a median of $782937.0 in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: skyrocketed 452.09% in 2023, then dropped 5.37% in 2024.
  • bioAffinity Technologies' Accounts Payables stood at $345042.0 in 2022, then skyrocketed by 75.28% to $604789.0 in 2023, then surged by 63.25% to $987311.0 in 2024, then fell by 4.71% to $940761.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Accounts Payables are $940761.0 (Q3 2025), $1.2 million (Q2 2025), and $1.4 million (Q1 2025).